Home・Aktien・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

214.68 -2.71

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

210

Max

223.06

Schlüsselkennzahlen
By Trading Economics
Einkommen	-36M -65M
Verkäufe	-4.8M 191M
EPS	-1.26
Gewinnspanne	-33.756
Angestellte	1,220
EBITDA	-36M -61M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+34.09% upside

Dividenden
By Acuity
Nächstes Ergebnis	2. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.2B 11B
Vorheriger Eröffnungskurs	217.39
Vorheriger Schlusskurs	214.68

Nachrichtenstimmung

By Acuity

54%

46%

251 / 340 Ranking in Healthcare

Axsome Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Axsome Therapeutics Inc Prognose

Kursziel

By TipRanks

34.09% Vorteil

12-Monats-Prognose

Durchschnitt 296.2 USD 34.09%

Hoch 380 USD

Tief 255 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Axsome Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Axsome Therapeutics Inc – Dist abgegeben haben.

Stimmung

By Acuity

251 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.